Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product

Journal of Biomedical Nanotechnology

Volumn 8, Issue 2, 2012, Pages 290-300

  Damasceno, Bolívar P G L ^a,b   Dominici, Victor A ^b   Urbano, Isabel A ^b   Silva, José A ^a   Araújo, Ivonete B ^b   Santos Magalhães, Nereide S ^c   Silva, Amanda K A ^b   Medeiros, Aldo C ^b   Oliveira, Anselmo G ^d   Egito, E Sócrates T ^b  

^a STATE UNIVERSITY OF PARAÍBA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Amphotericin B; Drug delivery system; Microemulsion; Nanotechnology; Pharmacotoxicity; Spectral studies

Indexed keywords

ADVERSE DRUG REACTIONS; ALBICANS; AMPHOTERICIN; AMPHOTERICIN B; ANTI-FUNGAL; AVERAGE SIZE; CLINICAL USE; COMMERCIAL PRODUCTS; DRUG CARRIER; DRUG DELIVERY SYSTEM; FUNGAL CELLS; FUNGAL INFECTION; HIGH INCIDENCE; HUMAN RED BLOOD CELL; MICELLAR SYSTEMS; PHARMACOTOXICITY; POTENTIAL APPLICATIONS; SAMPLE DILUTION; SPECTRAL STUDIES; UV SPECTRUM;

DRUG DELIVERY; FUNGI; MOLECULES; NANOTECHNOLOGY; PATIENT TREATMENT; PHOTON CORRELATION SPECTROSCOPY; SPECTROSCOPIC ANALYSIS; TOXICITY; ULTRAVIOLET SPECTROSCOPY;

MICROEMULSIONS;

AMPHOTERICIN B; DRUG CARRIER;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ERYTHROCYTE; HUMAN; HUMAN CELL; MICROEMULSION; PARTICLE SIZE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CELL SURVIVAL; DRUG CARRIERS; EMULSIONS; ERYTHROCYTES; HEMOGLOBINS; HUMANS; LINEAR MODELS; MALE; NANOPARTICLES; PARTICLE SIZE; POTASSIUM; SPECTROPHOTOMETRY;

EID: 84861468999     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1374     Document Type: Article

References (39)

1. G. Strauss and F. Kral, Borate complexes of amphotericin B polymeric species, and aggregates in aqueous solutions. Byopolymers 21, 1 (1982).
2. J. Bolard, How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta. 864, 257 (1986).
3. J. Brajtburg, W. G. Powderly, G. S. Kobayashi, and G. Medoff, Amphotericin B: Current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34, 183 (1990).
4. A. S. Janoff, W. R. Perkins, S. L. Saletan, and C. E. Swenson, Amphotericin B lipid complex (ABLCTM): A molecular rationale for the attenuation of amphotericin B related toxicities. J. Lip. Res. 3, 451 (1993).
5. J. Brajtburg and J. Bolard, Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9, 512 (1996).
6. E. S. T. Egito, I. B. Araujo, B. P. G. L. Damasceno, and J. C. Price, Amphotericin B/emulsion admixture interactions: An approach concerning the reduction of amphotericin B toxicity. J. Pharm. Sci. 91, 2354 (2002).
7. E. S. T. Egito, H. Fessi, M. Appel, G. Barratt, P. Legrand, J. Bolard, and J. P. Devissaguet, A morphological study of an amphotericin B emulsion-based delivery system. Int. J. Pharm. 145, 17 (1996).
8. V. Joly, R. Farinotti, L. Saint-Julien, M. Cheron, C. Carbon, and P. Yeni, In vitro renal toxicity, and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Ch. 38, 177 (1994).
9. F. P. Latorre, O. D. Sánchez, and M. V. A. Rabanal, Paciente con aspergilosis pulmonar: Indicación de la administración de una mezcla IV de anfotericina B en intralipid 20%. Farmácia Clínica 12, 31 (1995).
10. Y. Hong, P. J. Shaw, B. N. Tattam, C. E. Nath, J. W. Earl, K. R. Stephen, and A. J. McLachlan, Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. Eur. J. Clin. Pharmacol. 63, 165 (2007).
11. J. U. Junghanns, I. Buttle, R. H. Muller, I. B. Araujo, A. K. A. Silva, E. S. T. Egito, and B. Damasceno, SolEmuls((R)) technology: A way to overcome the drawback of parenteral administration of insoluble drugs. Pharm. Dev. Technol. 12, 437 (2007).
12. R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo, Relationship of pharmacokinetics, and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36, 299 (1992).
13. E. Esposito, F. Bortolotti, E. Menegatti, and R. Cortesi, Amphiphilic association systems for amphotericin B delivery. Int. J. Pharm. 260, 249 (2003).
14. K. C. Pestana, T. P. Formariz, C. M. Franzini, V. H. V. Sarmento, L. A. Chiavacci, M. V. Scarpa, E. S. T. Egito, and A. G. Oliveira, Oil-in-water lecithin-based microemulsions as a potential delivery system for amphotericin B. Colloid Surf B-Biointerfaces 66, 253 (2008).
15. P. P. Constantinides and S. H. Yiv, Particle size determination of phase-inverted water-in-oil microemulsions under different dilution and storage conditions. Int. J. Pharm. 115, 225 (1995).
16. T. R. Formariz, V. H. V. Sarmento, A. A. Silva-Junior, M. V. Scarpa, C. V. Santilli, and A. G. Oliveira, Doxorubicin biocompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. Colloid. Surf. B 51, 54 (2006).
17. A. G. Oliveira, M. V. Scarpa, M. A. Correa, L. F. R. Cera, and T. P. Formariz, Microemulsions: Structure, and application as drug delivery systems. Quim. Nova 27, 131 (2004).
18. S. Tenjarla, Microemulsions: An overview, and pharmaceutical applications. Crit. Rev. Ther. Drug. Carr. Syst. 16, 461 (1999).
19. D. Langevin, Microemulsions. Accounts Chem. Res. 21, 255 (1988).
20. H. L. Rosano, Microemulsions. J. Soc. Cosmet. Chem. 25, 609 (1974).
21. K. G. H. Silva, F. H. Xavier-Jr., I. E. G. Farias, A. K. A. Silva, J. A. Caudas-Neto, L. C. Souza, R. R. Santiago, F. Alexandrino- Jr., T. Nagashima, Jr., L. A. L. Soares, N. S. Santos-Magalhaes, and E. S. T. Egito, Stationary cuvette: A new approach to obtaining analytical curves by UV-VIS spectrophotometry. Phytochem. Anal. 20, 265 (2009).
22. P. A. Winsor, Hydrotropy, Solubilisation, and Related Emulsification Processes .1. To .4. Trans. Faraday Soc. 44, 376 (1948).
23. L. A. L. Soares, V. L. Bassani, G. González Ortega, and P. R. Petrovick, Total flavonoid determination for the quality control of aqueous extractives from Phyllanthus niruri L., Acta Farm Bonaerense 22, 203 (2003).
24. G. Fujii, J. E. Chang, T. Coley, and B. Steere, The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 36, 4959 (1997).
25. Y. Saka and T. Mita, Interaction of amphotericin B with cholesterol in monolayers, aqueous solutions, and phospholipid bilayers. J. Biochem. 123, 798 (1998).
26. J. Barwicz and P. Tancrede, The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterolcontaining phosphatidylcholine monolayers. Chem. Phys. Lipids. 85, 145 (1997).
27. C. Chapados, J. Barwicz, and I. Gruda, Separation of Overlapping Spectra from Evolving Systems Using Factor-Analysis .2. Amphotericin-B in Aqueous Propanol, and in Aqueous Lauroyl Sucrose. Biophys. Chem. 51, 71 (1994).
28. T. D. Madden, A. S. Janoff, and P. R. Cullis, Incorporation of Amphotericin-B into Large Unilamellar Vesicles Composed of Phosphatidylcholine and Phosphatidylglycerol. Chem. Phys. Lipids. 52, 189 (1990).
29. J. Bolard, P. Legrand, F. Heitz, and B. Cybulska, One sided action of amphotericin B on cholesterol containing membranes is determined by its self-association in the medium. Biochemistry 30, 5707 (1991).
30. R. L. Juliano, C. W. M. Grant, K. R. Barber, and M. A. Kalp, Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol. Pharmacol. 31, 1 (1987).
31. J. Bolard, M. Seigneuret, and G. Boudet, Interaction between phospholipid bilayer membranes, and the polyene antibiotic amphotericin B: Lipid state and cholesterol content dependence. Biochim. Biophys. Acta. 599, 280 (1980).
32. D. Attwood, C. Mallon, G. Ktistis, and C. J. Taylor, A study on factors influencing the droplet size in nonionic oil-in-water microemulsions. Int. J. Pharm. 88, 417 (1992).
33. C. Washington, S. J. Taylor, and S. S. Davis, The structure of colloidal formulations of amphotericin B. Int. J. Pharm. 46, 25 (1988).
34. E. S. T. Egito, H. Fessi, M. Appel, F. Puisieux, J. Bolard, and J. P. Devissaguet, New techniques for preparing submicronic emulsions: Application to amphotericin B. STP Pharma. Sci. 4, 155 (1994).
35. F. Gaboriau, M. Cheron, L. Leroy, and J. Bolard, Physico-chemical properties of the heat-induced 'superaggregates' of amphotericin B. Biophys Chem 66, 1 (1997).
36. L. Pisarik, V. Joly, S. Jullien, C. Carbon, and P. Yeni, Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes. J. Infect. Dis. 161, 1042 (1990).
37. R. Aboofazeli, C. B. Lawrence, S. R. Wicks, and M. J. Lawrence, Investigations into the formation, and characterization of phospholipid microemulsions. III. Pseudo-ternary phase diagrams of systems containing water-lecithin-isopropyl myristate, and either an alkanoic acid, amine, alkanediol, polyethylene glycol alkyl ether or alcohol as cosurfactant. Int. J. Pharm. 111, 63 (1994).
38. M. E. Dalmora, S. L. Dalmora, and A. G. Oliveira, Inclusion complex of piroxicam with beta-cyclodextrin, and incorporation in cationic microemulsion. In vitro drug release, and in vivo topical anti-inflammatory effect. Int. J. Pharm. 222, 45 (2001).
39. I. M. Asher, G. Schwartzman, and USASRG, Amphotericin, B, In: Analytical Profiles of Drug Substances, edited by K. Florey, Academic Press, New York (1972), Vol. 6, pp. 1-42.